Table 3.
Subgroup analysis for comparing DPP4 inhibitors with other OADS on MAGE.
| Datasets | MD (95% CI) | P for subgroup effect | I2 | P for subgroup difference | |
|---|---|---|---|---|---|
| Design | |||||
| Crossover | 3 | -0.35 [-1.03, 0.33] | 0.31 | 0% | |
| Parallel group | 12 | -0.74 [-1.04, -0.45] | < 0.001 | 38% | 0.30 |
| Patient number | |||||
| ≤ 35 | 9 | -0.74 [-1.09, -0.39] | < 0.001 | 0% | |
| > 35 | 6 | -0.66 [-1.09, -0.23] | 0.003 | 59% | 0.78 |
| Mean age (years) | |||||
| ≤ 58 | 7 | -0.63 [-1.06, -0.19] | 0.005 | 0% | |
| > 58 | 8 | -0.72 [-1.08, -0.36] | < 0.001 | 51% | 0.74 |
| Male (%) | |||||
| ≤ 65 | 7 | -0.57 [-0.98, -0.16] | 0.006 | 51% | |
| > 65 | 7 | -0.89 [-1.24, -0.54] | < 0.001 | 0% | 0.25 |
| Baseline HbA1c (%) | |||||
| ≤ 7.5 | 7 | -0.60 [-1.13, -0.07] | 0.03 | 55% | |
| > 7.5 | 8 | -0.62 [-0.87, -0.37] | < 0.001 | 0% | 0.94 |
| T2DM duration (years) | |||||
| ≤ 5 | 5 | -1.16 [-1.54, -0.79] | < 0.001 | 0% | |
| > 5 | 6 | -0.48 [-0.75, -0.22] | < 0.001 | 0% | 0.004 |
| Background treatment | |||||
| Drug naïve | 5 | -0.52 [-1.02, -0.02] | 0.04 | 16% | |
| With OAD | 8 | -0.80 [-1.19, -0.41] | < 0.001 | 57% | |
| Drug naïve or with OAD | 2 | -0.67 [-1.27, -0.08] | 0.03 | 59% | 0.69 |
| Treatment duration (days) | |||||
| ≤ 28 | 6 | -0.62 [-1.02, -0.23] | 0.002 | 0% | |
| > 28 | 9 | -0.74 [-1.11, -0.37] | < 0.001 | 48% | 0.68 |
| CGM/FGM time (hours) | |||||
| 24 or 48 | 8 | -0.41 [-0.66, -0.15] | 0.002 | 0% | |
| 72 | 7 | -1.05 [-1.37, -0.73] | < 0.001 | 5% | 0.002 |
| Quality score | |||||
| 3 | 7 | -0.67 [-1.14, -0.20] | 0.005 | 34% | |
| 4 | 4 | -0.70 [-1.33, -0.07] | 0.03 | 53% | |
| 5 | 4 | -0.55 [-0.84, -0.25] | < 0.001 | 0% | 0.85 |
DPP4, dipeptidyl-peptidase 4; HbA1c, glycosylated hemoglobin; T2DM, type 2 diabetes mellitus; OAD, oral antidiabetic drug; MAGE, mean amplitude of glycemic excursions; MD, mean difference; CI, confidence interval; CGM, continuous glucose monitoring; FGM, flash glucose monitoring.